Richard Burr: “If DIY is not part of this program, then I don't see how I could support this program, even consider it.”

Without Orrin, we wouldn't have a generic drug industry.

I hope to receive that response soon.

I question whether the agreements both passed and proposed reflect a good deal for patients they are designed to serve.

Nobody has worked harder on this issue, I think, on the Hill than I have.